These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9562693)

  • 21. Manipulation of HIV-1 gp120-specific immune responses elicited via gene gun-based DNA immunization.
    Prayaga SK; Ford MJ; Haynes JR
    Vaccine; 1997; 15(12-13):1349-52. PubMed ID: 9302743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen.
    Moss RB; Giermakowska WK; Wallace MR; Savary JR; Jensen FC; Carlo DJ
    AIDS; 2000 Nov; 14(16):2475-8. PubMed ID: 11101057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.
    Vijayan A; García-Arriaza J; Raman SC; Conesa JJ; Chichón FJ; Santiago C; Sorzano CÓ; Carrascosa JL; Esteban M
    PLoS One; 2015; 10(7):e0133595. PubMed ID: 26208356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice.
    Kawamura M; Wang X; Uto T; Sato K; Ueno M; Akagi T; Hiraishi K; Matsuyama T; Akashi M; Baba M
    J Med Virol; 2005 May; 76(1):7-15. PubMed ID: 15778965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
    Akagi T; Kawamura M; Ueno M; Hiraishi K; Adachi M; Serizawa T; Akashi M; Baba M
    J Med Virol; 2003 Feb; 69(2):163-72. PubMed ID: 12683403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.
    Fonseca DM; Silva CL; Paula MO; Soares EG; Marchal G; Horn C; Bonato VL
    Immunology; 2007 Aug; 121(4):508-17. PubMed ID: 17433075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neither interleukin-6 nor signalling via tumour necrosis factor receptor-1 contribute to the adjuvant activity of Alum and Freund's adjuvant.
    Brewer JM; Conacher M; Gaffney M; Douglas M; Bluethmann H; Alexander J
    Immunology; 1998 Jan; 93(1):41-8. PubMed ID: 9536117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor alpha and human immunodeficiency virus-specific functional immune responses after immunization with Gp120-depleted, inactivated HIV-1 in incomplete Freund's adjuvant (REMUNE) in HIV-1-seropositive subjects.
    Moss RB; Li L; Giermakowska WK; Lanza P; Turner JL; Wallace MR; Jensen FC; Richieri SP; Daigle AE; Theofan G; Carlo DJ
    J Hum Virol; 1998; 1(2):77-81. PubMed ID: 10195235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis.
    Zheng H; Zhang H; Liu F; Qi Y; Jiang H
    Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
    PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.
    Abdel-Motal U; Wang S; Lu S; Wigglesworth K; Galili U
    J Virol; 2006 Jul; 80(14):6943-51. PubMed ID: 16809300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-1beta partially alleviates cyclosporin A-induced suppression of IgG1 isotype response to thyroglobulin in BALB/c mice in vivo.
    Dalai SK; Miriyala B; Kar SK
    Immunology; 1998 Sep; 95(1):83-9. PubMed ID: 9767461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.
    Liu F; Mboudjeka I; Shen S; Chou TH; Wang S; Ross TM; Lu S
    Vaccine; 2004 Apr; 22(13-14):1764-72. PubMed ID: 15068860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions.
    Hiroi T; Goto H; Someya K; Yanagita M; Honda M; Yamanaka N; Kiyono H
    J Immunol; 2001 Nov; 167(10):5862-7. PubMed ID: 11698461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
    Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
    Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Montanide ISA 71 VG is Advantageous to Freund's Adjuvant in Immunization Against S. aureus Infection of Mice.
    Klimka A; Michels L; Glowalla E; Tosetti B; Krönke M; Krut O
    Scand J Immunol; 2015 May; 81(5):291-7. PubMed ID: 25689117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoproliferation in HIV-1-infected patients undergoing active HIV-1-specific immunotherapy.
    Trauger RJ; Giermakowska W; Wormsley S; Turner J; Jensen FC; Carlo DJ
    Clin Exp Immunol; 1995 Apr; 100(1):7-12. PubMed ID: 7697926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization with an interferon-gamma-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120.
    McCormick AL; Thomas MS; Heath AW
    J Infect Dis; 2001 Dec; 184(11):1423-30. PubMed ID: 11709784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.